BioPharmSignal logoBioPharmSignal

Biotech News

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Pulse Biosciences (PLSE)Pulse BiosciencesCompany update

Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. HAYWARD, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary

Open original release

Related news

PLSEPulse Biosciences2026-04-07 11:00 EST

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

PLSEPulse Biosciences2026-03-12 11:00 EST

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

ICCMIceCure Medical2026-07-27 12:32 EST

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

DCTHDelcath Systems2026-04-06 12:30 EST

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

HYPRHyperfine2026-04-29 12:15 EST

Hyperfine Swoop® System Introduced as India’s First Portable MRI for Bedside Brain Imaging at the Country’s Leading Medical Institution

HYPRHyperfine2026-07-01 12:15 EST

Hyperfine Announces European Launch of Next-Generation Swoop® System

ANGOAngioDynamics2026-05-13 13:00 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

TMCITreace Medical Concepts2026-05-08 11:05 EST

Treace Medical Concepts Reports First Quarter 2026 Financial Results

OMOutset Medical2026-05-07 20:02 EST

Outset Medical Reports First-Quarter Results

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

View all latest news

Pulse Biosciences

Pulse Biosciences is a medical technology company focused on nano-pulse stimulation and nonthermal cellular treatments. Its platform is intended to create new ways to treat tissue while preserving surrounding structures.

Recent company news

PLSEPulse Biosciences2026-05-27 20:05 EST

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

PLSEPulse Biosciences2026-05-12 11:00 EST

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

PLSEPulse Biosciences2026-05-08 11:00 EST

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

PLSEPulse Biosciences2026-05-04 11:00 EST

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

PLSEPulse Biosciences2026-04-25 17:00 EST

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

Stock data

Close
32.79 USD
Market cap
1.68B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States